Pfizer (PFE) Financials

Pfizer’s latest quarter shows a meaningful rebound in earnings and cash generation versus the weak end of 2025, but the longer-term picture still points to pressure from lower revenue, high intangibles, and a still-elevated debt load.

In Q1 2026, Pfizer reported $14.45 billion in revenue and $2.69 billion in consolidated net income, compared with a $1.64 billion loss in Q4 2025. Operating income also improved sharply to $4.03 billion, up from $2.87 billion in the prior quarter. Cash flow turned positive as well, with $2.62 billion in operating cash flow and a $563 million increase in cash and equivalents.

That said, the recovery is coming off a very volatile multi-year period. Pfizer’s pandemic-era revenue and earnings have normalized lower, and the company still relies heavily on investment income, debt markets, and large non-cash accounting items to manage its balance sheet.

• Quarterly earnings rebounded strongly: Q1 2026 net income was $2.69 billion, versus a $1.64 billion loss in Q4 2025.
• Operating income improved materially: Q1 2026 operating income of $4.03 billion was up from $2.87 billion in Q4 2025.
• Operating cash flow remains solid: Pfizer generated $2.62 billion in operating cash flow in Q1 2026.
• Liquidity is still substantial: The company ended Q1 2026 with $1.7 billion in cash, $11.4 billion in short-term investments, and $1.6 billion in long-term investments.
• Revenue stabilized quarter over quarter: Q1 2026 revenue of $14.45 billion was close to the Q1 2025 level of $13.72 billion and better than the soft Q4 2025 result.
• Gross margin improved sequentially: Q1 2026 gross profit of $10.90 billion represented a healthy mix versus revenue, helped by lower cost of revenue.
• Balance sheet remains large and asset-heavy: Total assets were $207.6 billion, but a large share was tied up in goodwill ($71.4 billion) and intangible assets ($52.6 billion).
• Debt remains significant: Pfizer carried $60.6 billion of long-term debt and $3.9 billion of short-term debt at the end of Q1 2026.
• Dividends still absorb a lot of cash: Pfizer paid $2.45 billion in dividends in Q1 2026, which remains a major cash outflow.
• Operating capital was a drag this quarter: Changes in operating assets and liabilities reduced operating cash flow by $1.74 billion in Q1 2026.

Looking back over the last four years, Pfizer’s trend is clear: 2022 was exceptionally strong, 2023 weakened sharply, and 2024-2025 were a reset period with much lower profits and more uneven quarterly results. For example, Q1 2023 revenue was $18.49 billion and net income was $5.56 billion, while Q1 2026 revenue was $14.45 billion and net income was $2.69 billion. That shows the business is still operating well below peak conditions.

Cash flow has also been volatile. Pfizer posted strong operating cash flow in some quarters, such as $6.72 billion in Q4 2024 and $4.60 billion in Q3 2025, but it also had negative operating cash flow in Q2 2025. That inconsistency matters for investors because it can affect debt reduction, buybacks, and dividend flexibility.

The balance sheet is stable but not pristine. Total equity has been fairly steady around the low-$90 billion range recently, but retained earnings, treasury stock, and accumulated losses show the impact of years of large capital returns and fluctuating profitability. Pfizer’s goodwill and intangible assets are also very large, which means future impairments would not be surprising if performance weakens further.

Bottom line: Pfizer is showing signs of near-term operational recovery, but the longer-term story is still one of normalization from a much stronger prior era. Investors will likely want to see more consistent revenue, better operating cash flow, and continued debt management before calling the turnaround complete.